Physician profile
Kimberly Helms
NPI 1629726229
$9,039.32
in general payments reported to CMS, 2019-2025
24 companies · $1,626 in 2025
The $1,626 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Registered Nurse) providers received nationally (typical 2025 total: $137).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $123 · 2023: $1,600 · 2024: $5,691 · 2025: $1,626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,395 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,383 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,395.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,382.50 |
| Education | $138.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $3,539.81 | 2023-2025 | Loreev Xr |
| Otsuka America Pharmaceutical, INC. | $806.35 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $682.17 | 2023-2025 | |
| Alkermes, INC. | $648.90 | 2022-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $640.12 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $450.59 | 2023-2025 | Spravato, Invega Sustenna |
| Lundbeck LLC | $389.38 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $358.52 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Corium, LLC | $273.84 | 2023-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $227.13 | 2024-2025 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $165.24 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $128.98 | 2023-2024 | Auvelity |
| Neos Therapeutics, Lp | $108.06 | 2023-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Tris Pharma INC | $100.14 | 2022-2025 | Dyanavel Xr |
| Neurocrine Biosciences, INC. | $95.00 | 2023-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $89.83 | 2023-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $71.21 | 2022-2023 | Jornay Pm |
| Merck Sharp & Dohme LLC | $49.96 | 2023 | Belsomra |
| Collegium Pharmaceutical, INC. | $49.04 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $41.91 | 2023-2025 | Xelstrym |
| Bausch Health US, LLC | $39.11 | 2025 | Aplenzin, Wellbutrin |
| Vanda Pharmaceuticals INC. | $37.85 | 2025 | Fanapt, Hetlioz |
| Novo Nordisk INC | $33.13 | 2023 | Wegovy |
| Acadia Pharmaceuticals INC | $13.05 | 2023 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Helms listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.